The association between patient-reported and objective oral anticancer medication adherence measures: A systematic review

Oncology Nursing Forum

Volumn 43, Issue 5, 2016, Pages 576-582

  Atkinson, Thomas M ^a   Rodríguez, Vivian M ^a   Gordon, Mallorie ^a   Avildsen, Isabelle K ^a   Emanu, Jessica C ^a   Jewell, Sarah T ^b   Anselmi, Kimberly A ^a   Ginex, Pamela K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Medication adherence; Neoplasms; Oral medicine; Patient outcome assessment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; QUESTIONNAIRE; SELF REPORT; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASMS; SELF REPORT; SURVEYS AND QUESTIONNAIRES;

EID: 84983735469     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/16.ONF.576-582     Document Type: Review

References (39)

1. Addeo, R., Iodice, P., Maiorino, L., Febbraro, A., Incoronato, P., Pisano, A., . . . Del Prete, S. (2015). Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: Exacampania group study. Breast Journal, 21, 326-328. doi:10.1111/tbj.12409
2. Bedell, C.H. (2003). A changing paradigm for cancer treatment: The advent of new oral chemotherapy agents. Clinical Journal of Oncology Nursing, 7(Suppl.), 5-9. doi:10.1188/03.CJON.S6.5-9
3. Bestvina, C.M., Zullig, L.L., Rushing, C., Chino, F., Samsa, G.P., Altomare, I., . . . Zafar, S.Y. (2014). Patient-oncologist cost communication, financial distress, and medication adherence. Journal of Oncology Practice, 10, 162-167. doi:10.1200/JOP.2014.001406
4. Borner, M.M., Schoffski, P., de Wit, R., Caponigro, F., Comella, G., Sulkes, A., . . . Fumoleau, P. (2002). Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. European Journal of Cancer, 38, 349-358. doi:10.1016/s0959-8049(01)00371-9
5. Boucher, J., Lucca, J., Hooper, C., Pedulla, L., & Berry, D.L. (2015). A structured nursing intervention to address oral chemotherapy adherence in patients with non-small cell lung cancer. Oncology Nursing Forum, 42, 383-389. doi:10.1188/15.ONF.383-389
6. Daouphars, M., Ouvry, M., Lenain, P., Rouvet, J., Jardin, F., Bubenheim, M., & Varin, R. (2013). Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia. Pharmacotherapy, 33, 152-156. doi:10.1002/phar.1174
7. Darkow, T., Henk, H.J., Thomas, S.K., Feng, W., Baladi, J.F., Goldberg, G.A., . . . Cortes, J. (2007). Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics, 25, 481-496.
8. Deutsch, S., Koerner, P., Miller, R.T., Craft, Z., & Fancher, K. (2016). Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program. Journal of Oncology Pharmacy Practice, 22, 68-75. doi:10.1177/1078155214547664
9. Downs, S.H., & Black, N. (1998). The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health, 52, 377-384.
10. Fallowfield, L., Atkins, L., Catt, S., Cox, A., Coxon, C., Langridge, C., . . . Price, M. (2006). Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Annals of Oncology, 17, 205-210. doi:10.1093/annonc/mdj044
11. Foulon, V., Schoffski, P., & Wolter, P. (2011). Patient adherence to oral anticancer drugs: An emerging issue in modern oncology. Acta Clinica Belgica, 66, 85-96. doi:10.1179/ACB.66.2.2062525
12. Gebbia, V., Bellavia, M., Banna, G.L., Russo, P., Ferraù, F., Tralongo, P., & Borsellino, N. (2013). Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clinical Lung Cancer, 14, 390-398. doi:10.1016/j.cllc.2012.11.007
13. Ibrahim, A.R., Eliasson, L., Apperley, J.F., Milojkovic, D., Bua, M., Szydlo, R., . . . Marin, D. (2011). Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 117, 3733-3736. doi:10.1182/blood-2010-10-309807
14. Kavookjian, J., & Wittayanukorn, S. (2015). Interventions for adherence with oral chemotherapy in hematological malignancies: A systematic review. Research in Social and Administrative Pharmacy, 11, 303-314. doi:10.1016/j.sapharm.2014.08.006
15. Macintosh, P.W., Pond, G.R., Pond, B.J., Leung, V., & Siu, L.L. (2007). A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. European Journal of Cancer Care, 16, 380-386. doi:10.1111/j.1365-2354.2006.00758.x
16. Marin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., . . . Khorashad, J.S. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28, 2381-2388.
17. Moore, S. (2007). Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nursing, 30, 112-122. doi:10.1097/01.NCC.0000265009.33053.2d
18. O'Neill, V.J., & Twelves, C.J. (2002). Oral cancer treatment: Developments in chemotherapy and beyond. British Journal of Cancer, 87, 933-937. doi:10.1038/sj.bjc.6600591
19. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353, 487-497. doi:10.1056/NEJMra050100
20. Palmieri, F.M., & Barton, D.L. (2007). Challenges of oral medications in patients with advanced breast cancer. Seminars in Oncology Nursing, 23(Suppl.), S17-S22. doi:10.1016/j.soncn.2007.10.004
21. Park, L.G., Howie-Esquivel, J., & Dracup, K. (2014). A quantitative systematic review of the efficacy of mobile phone interventions to improve medication adherence. Journal of Advanced Nursing, 70, 1932-1953. doi:10.1111/jan.12400
22. Puts, M.T., Tu, H.A., Tourangeau, A., Howell, D., Fitch, M., Springall, E., & Alibhai, S.M. (2014). Factors influencing adherence to cancer treatment in older adults with cancer: A systematic review. Annals of Oncology, 25, 564-577. doi:10.1093/annonc/mdt433
23. Richardson, J.L., Shelton, D.R., Krailo, M., & Levine, A.M. (1990). The effect of compliance with treatment on survival among patients with hematologic malignancies. Journal of Clinical Oncology, 8, 356-364.
24. Ruddy, K., Mayer, E., & Partridge, A. (2009). Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59, 56-66. doi:10.3322/caac.20004
25. Sadahiro, S., Ohki, S., Yamaguchi, S., Takahashi, T., Otani, Y., Tsukikawa, S., . . . Makuuchi, H. (2000). Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Complicance Study Group, Kanagawa, Japan. Cancer Chemotherapy and Pharmacology, 46, 180-184. doi:10.1007/s002800000146
26. Schneider, S.M., Adams, D.B., & Gosselin, T. (2014). A tailored nurse coaching intervention for oral chemotherapy adherence. Journal of the Advanced Practitioner in Oncology, 5, 163-172.
27. Schneider, S.M., Hess, K., & Gosselin, T. (2011). Interventions to promote adherence with oral agents. Seminars in Oncology Nursing, 27, 133-141. doi:10.1016/j.soncn.2011.02.005
28. Servick, K. (2014). Biomedicine. 'Nonadherence': A bitter pill for drug trials. Science, 346, 288-289. doi:10.1126/science.346.6207.288
29. Shi, L., Liu, J., Koleva, Y., Fonseca, V., Kalsekar, A., & Pawaskar, M. (2010). Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. PharmacoEconomics, 28, 1097-1107. doi:10.2165/11537400-000000000-00000
30. Soria, J.C., Blay, J.Y., Spano, J.P., Pivot, X., Coscas, Y., & Khayat, D. (2011). Added value of molecular targeted agents in oncology. Annals of Oncology, 22, 1703-1716. doi:10.1093/annonc/mdq675
31. Spoelstra, S.L., & Given, C.W. (2011). Assessment and measurement of adherence to oral antineoplastic agents. Seminars in Oncology Nursing, 27, 116-132. doi:10.1016/j.soncn.2011.02.004
32. Streeter, S.B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011). Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. Journal of Oncology Practice, 7(Suppl.), 46s-51s. doi:10.1200/JOP.2011.000316
33. Thanki, K., Gangwal, R.P., Sangamwar, A.T., & Jain, S. (2013). Oral delivery of anticancer drugs: Challenges and opportunities. Journal of Controlled Release, 170, 15-40. doi:10.1016/j.jconrel.2013.04.020
34. Timmers, L., Boons, C.C., Kropff, F., van de Ven, P.M., Swart, E.L., Smit, E.F., . . . Hugtenburg, J.G. (2014). Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncologica, 53, 259-267. doi:10.3109/0284186X.2013.844353
35. Timmers, L., Boons, C.C., Moes-Ten Hove, J., Smit, E.F., van de Ven, P.M., Aerts, J.G., . . . Hugtenburg, J.G. (2015). Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 141, 1481-1491. doi:10.1007/s00432-015-1935-0
36. Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., & Van Hecke, A. (2013). Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treatment Reviews, 39, 610-621. doi:10.1016/j.ctrv.2012.12.014
37. Verma, S., Madarnas, Y., Sehdev, S., Martin, G., & Bajcar, J. (2011). Patient adherence to aromatase inhibitor treatment in the adjuvant setting. Current Oncology, 18(Suppl. 1), S3-S9.
38. Walter, T., Wang, L., Chuk, K., Ng, P., Tannock, I.F., & Krzyzanowska, M.K. (2013). Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine. Journal of Oncology Pharmacy Practice, 20, 249-256. doi:10.1177/1078155213501100
39. Waterhouse, D.M., Calzone, K.A., Mele, C., & Brenner, D.E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 11, 1189-1197.